Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis

Journal of Crohn's and Colitis

Volumn 8, Issue 1, 2014, Pages 85-86

  Teich, Niels ^a   Klugmann, Tobias ^a  

^a Und Stoffwechselkrankheiten ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CLOBETASOL PROPIONATE; CYCLOSPORIN; GENTAMICIN; INFLIXIMAB; MESALAZINE; PREDNISOLONE; TACROLIMUS;

ADULT; ANAPHYLAXIS; CASE REPORT; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUSHING; GEL; HUMAN; HYPOTENSION; LETTER; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REMISSION; SIDE EFFECT; TACHYPNEA; ULCERATIVE COLITIS; WOUND FLUID;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; GELS; HUMANS; PYODERMA GANGRENOSUM; RECURRENCE;

EID: 84890057993     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.06.003     Document Type: Letter

References (5)

1. Pereira N., Brites M.M., Gonçalo M., Tellechea O., Figueiredo A. Pyoderma gangrenosum - a review of 24 cases observed over 10years. Int J Dermatol 2013, [in press].
2. Brooklyn T.N., Dunnill M.G., Shetty A., Bowden J.J., Williams J.D., Griffiths C.E., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55:505-509.
3. Ahronowitz I., Harp J., Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol Jun 1 2012, 13(3):191-211.
4. Wallace H.J., Stacey M.C. Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers-correlations to healing status. J Invest Dermatol 1998, 110:292-296.
5. Streit M., Beleznay Z., Braathen L.R. Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J 2006, 3:171-179.